Literature DB >> 29033771

Malignant Gastric Outlet Obstruction from Pancreatic Cancer.

Clare McGrath1, Adrian Tsang2, Harrish Nithianandan2, Eric Nguyen2, Patrick Bauer3, Kristopher Dennis3.   

Abstract

Patients with advanced-stage pancreatic cancer are typically burdened by many symptoms that impair functioning and worsen quality of life. We report an exceptional case of a 73-year-old woman with T4N1M0 adenocarcinoma of the uncinate process of the pancreas who developed significant gastric outlet obstruction - an uncommon yet potentially life-threatening complication of disease progression. She developed progressive abdominal pain and emesis, and profound dilatation of her stomach was detected on a radiation therapy simulation CT scan that required urgent decompression. Malignant gastric outlet obstruction must be included in the differential diagnosis when patients with known advanced disease of the pancreas present with obstructive upper gastrointestinal symptoms.

Entities:  

Keywords:  Duodenum; Gastric outlet obstruction; Obstruction; Pancreatic cancer; Stomach

Year:  2017        PMID: 29033771      PMCID: PMC5637001          DOI: 10.1159/000480070

Source DB:  PubMed          Journal:  Case Rep Gastroenterol        ISSN: 1662-0631


Introduction

Gastric outlet obstruction (GOO) can cause significant morbidity including severe weight loss, malnutrition, dehydration, and electrolyte abnormalities [1, 2]. GOO can greatly compromise quality of life and can progress to become life-threatening in advanced cases. GOO typically develops in patients with pancreatic cancer due to progression of the primary tumor causing extrinsic compression of the duodenum, and less commonly from lymphadenopathy, carcinomatosis, or liver metastases. Pancreatic cancer is the most common cause of malignant GOO in the western world [3]. Around 15–20% of patients with pancreatic cancer develop some degree of GOO [3]. Nonbilious vomiting and nausea are the cardinal symptoms of advanced obstruction [1, 2]. The typical goals of palliative treatments in this setting are to establish a means by which patients can maintain their oral food intake, reduce pain, nausea, and vomiting, and improve their quality of life. We report here an exceptional case of malignant GOO that necessitated urgent decompression.

Case Presentation

A 73-year-old woman presented to her family physician with an unexplained drop in weight from 90 to 65 kg in the last 5 months, upper abdominal pain and nausea, acholic stools, and jaundice. She had a history of depression, osteoarthritis, dyslipidemia, a previous laparoscopic cholecystectomy 15 years earlier, and a mesenteric venous thrombosis. She declared a smoking history of 23 pack-years, consumed less than 1 alcoholic drink per week, and denied any use of illicit drugs. The patient's family history was significant: her mother had gall bladder cancer and two maternal aunts had liver and lung cancers, respectively. Two endoscopic retrograde cholangiopancreatographies (ERCPs) were performed which revealed a common bile duct stricture – a “fuzzy” possibly mass-like area in the adjacent pancreas – and a common bile duct stent was placed to relieve the obstruction. The stomach appeared unremarkable on standard and retroflex views. Further imaging determined that the “fuzzy” appearance of the pancreas was likely due to a perforation from the first ERCP and not a mass. Three months later, following an episode of cholangitis, she underwent a choledochojejunostomy that revealed an unresectable pancreatic mass extensively infiltrating the root of the small bowel mesentery. A biopsy of the mesentery extension of the mass confirmed a well-differentiated adenocarcinoma. Imaging confirmed her disease as T4N1M0 adenocarcinoma of the uncinate process of the pancreas. Worsening symptoms suggestive of GOO led to another ERCP; it revealed no significant evidence of duodenal obstruction up to the fourth section of the duodenum so a duodenal stent was not placed. As a result of her advanced disease the patient was referred for consideration of palliative radiotherapy to relieve her gastrointestinal symptoms. At that time she had lost an additional 6 kg in the past month, and was admitted to hospital with an Eastern Cooperative Oncology Group (ECOG) performance status of 3. She took regular venlafaxine, risperidone, ramipril, rosuvastatin, furosemide, potassium chloride, and dalteparin, and had recently been prescribed senna glycoside, lactulose, docusate, hydromorphone, dexamethasone, and metoclopramide. She complained of aching pain across her epigastrium and upper abdominal quadrants, anorexia, and fatigue. While following a predominantly liquid-only diet, she was suffering from new bouts of projectile vomiting, nausea, and distention. In a 3-week period, her symptoms had worsened to the point where she could barely tolerate oral solids or liquids. On examination she was obese and tender over the epigastrium but devoid of distinct palpable masses. Her abdomen was somewhat tympanic but body habitus obscured more detailed findings. She underwent a CT scan for radiation planning which surprisingly revealed profound dilatation of the stomach and proximal duodenum (Fig. 1, 2) with extrinsic compression and likely invasion of the duodenum by the uncinate mass. She was diagnosed with malignant GOO, and several liters of fluid were urgently removed via nasogastric tube suction. In retrospect, it was thought that the obstruction had progressed from transient to complete since the time of her last endoscopy 13 days previously that had ruled out obstruction. Radiation therapy was cancelled and a gastrojejunostomy was performed to bypass the obstruction and relieve her symptoms.
Fig. 1

A coronal plane CT image showing profound dilation of the stomach spanning the abdominal cavity.

Fig. 2

A sagittal plane CT image showing profound dilatation of the stomach spanning the abdominal cavity.

A week later, her symptoms had resolved and she was able to consume solid foods. She was discharged home and began palliative gemcitabine. Unfortunately, the patient later became too weak to complete her third cycle, and 4 months following the diagnosis of GOO she passed away in a hospice.

Discussion

GOO typically presents with nausea and nonbilious vomiting, but signs of anorexia, malnutrition, dehydration, and epigastric fullness may present earlier. When patients with pancreatic cancer complain of these symptoms it is important to rule out early obstruction and to stay vigilant for changes in symptoms; our patient's case demonstrates how rapidly disease can progress in a short time. Both the proximal and distal duodenum are vulnerable to external compression from masses in the pancreatic head and uncinate process due to their close proximity and long adjacent course. Initial steps in GOO management include adequate control of pain, decompression with a nasogastric tube, and then consideration of the most effective method to restore adequate nutritional transit, typically via stent placement or surgical diversion [4]. Patients presenting with malignant GOO are often faced with a poor prognosis and limited life expectancy. It is important to determine whether surgical intervention is warranted by considering the patient's overall burden of disease, prognosis, and personal wishes. In cases of advanced pancreatic disease, radiation therapy is considered a treatment option for malignant obstruction. However, radiation therapy often takes weeks to relieve symptoms of GOO, if effective. More immediate measures, such as stenting or fluoroscopic/endoscopic placement of a feeding tube through the stricture, are rapid, easily accessible, and can provide nourishment in the short term while waiting for a response from radiation therapy. In more advanced cases, surgical diversion is an option, but this is typically only offered when there is a reasonable expectation of the patient receiving life-prolonging therapy in the near future. Developing an optimal care plan for GOO from pancreatic cancer necessitates a multidisciplinary approach to palliation with input from gastroenterologists, surgeons, radiation and medical oncologists, and palliative care physicians. This extraordinary case demonstrates the importance of considering GOO in the differential diagnosis of upper gastrointestinal symptoms in this patient population. Optimal symptom relief and treatment requires the input of a broad multidisciplinary team. Radiation therapy is an option for treatment but does not relieve symptoms quickly; optimization of endoscopic and surgical options should be considered first to quickly re-establish adequate nutritional intake.

Statement of Ethics

Approval from an ethics committee is not required for case reports at our institution.

Disclosure Statement

The authors have no conflicts of interest to disclose.
  4 in total

1.  Expandable metal stent placement for gastric outlet obstruction.

Authors:  T H Baron; R Schöfl; A Puespoek; Y Sakai
Journal:  Endoscopy       Date:  2001-07       Impact factor: 10.093

2.  Surgical palliation for pancreatic cancer. The UCLA experience.

Authors:  S M Singh; W P Longmire; H A Reber
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

3.  Long-term outcome of palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer in patients with good performance status: endoscopic stenting versus surgery.

Authors:  Jin Hee No; Sang Woo Kim; Chul-Hyun Lim; Jin Su Kim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Myung-Gyu Choi; Kyu Yong Choi
Journal:  Gastrointest Endosc       Date:  2013-03-20       Impact factor: 9.427

Review 4.  Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review.

Authors:  Suzanne M Jeurnink; Casper H J van Eijck; Ewout W Steyerberg; Ernst J Kuipers; Peter D Siersema
Journal:  BMC Gastroenterol       Date:  2007-06-08       Impact factor: 3.067

  4 in total
  1 in total

1.  EUS-guided stent placement for afferent limb and gastrojejunal obstruction in a patient with pancreatic cancer.

Authors:  Qais Dawod; Danny Issa; Shawn L Shah; Sanad Dawod; Reem Z Sharaiha
Journal:  VideoGIE       Date:  2021-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.